How to Test for the APOE4 Gene and What Results Mean

Testing for the APOE4 gene can be done through a direct-to-consumer genetic testing service or through a clinical genetic test ordered by your doctor, and results tell you which combination of the three common APOE variants you carry. The reason people increasingly want this information goes well beyond curiosity: APOE genotype now directly affects eligibility decisions and safety monitoring for new Alzheimer’s drugs, influences how aggressively you might want to manage cholesterol, and can shape long-term lifestyle planning. But the results are probabilistic, not deterministic, and interpreting them well requires more context than most testing services provide.

How the Testing Works

There are two main routes to finding out your APOE genotype. The first is a direct-to-consumer (DTC) test from a company like 23andMe, which includes APOE status in its health reports. You spit into a tube, mail it back, and get results in a few weeks. The second is a clinical genetic test, ordered by a physician or genetic counselor, which uses a blood draw or cheek swab and is processed by a certified laboratory. Clinical tests are sometimes covered by insurance, particularly if you have symptoms of cognitive decline or are being evaluated for one of the newer Alzheimer’s therapies.

The DTC route is simpler and cheaper, but it comes with a tradeoff: you get a result without built-in guidance on what to do with it. Clinical testing, by contrast, usually comes with genetic counseling before and after disclosure. Current practice guidelines for APOE genotyping recommend genetic counseling for all types of testing.¹ That recommendation exists for good reason, as the emotional weight of APOE results can catch people off guard, and the numbers need context to be useful rather than frightening.

The Three APOE Variants

Everyone carries two copies of the APOE gene, one from each parent. The gene comes in three common versions: ε2, ε3, and ε4. Your genotype is some combination of these two copies, giving you one of six possible pairings: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, or ε4/ε4.

The APOE protein’s main job is transporting lipids, especially cholesterol, through the bloodstream and inside the brain. It plays a central role in maintaining and repairing neurons.² The three variants do this job with different levels of efficiency. APOE3 is the most common version and is considered the baseline for average risk. APOE2 is relatively protective against Alzheimer’s disease, while APOE4 increases risk.³ The APOE4 protein is poorly lipidated compared with APOE3, which means it does not transport fats between brain cells as effectively, and that inefficiency appears to undermine neuronal health over time.⁴

What APOE4 Results Mean for Alzheimer’s Risk

If your test comes back showing one or two copies of ε4, the first question is usually about Alzheimer’s disease. The risk increase is real, but it scales steeply with dose. In a large study across multiple populations, people with one copy of ε4 (the ε3/ε4 genotype) had roughly three and a half times higher odds of developing Alzheimer’s compared to those with the ε3/ε3 baseline, while those with two copies (ε4/ε4) had about thirteen times higher odds in White populations.⁵ Those are big numbers, but they describe odds ratios across populations, not your personal fate. Many ε4/ε4 carriers live into their eighties and nineties without developing dementia, and many people with Alzheimer’s carry no ε4 at all.

If your result shows ε2/ε3 or ε2/ε2, you can breathe a little easier. APOE2 appears to reduce Alzheimer’s risk through multiple pathways, both by limiting the buildup of amyloid plaques and through mechanisms independent of amyloid.³ The ε2/ε4 combination is trickier to interpret since the two variants pull in opposite directions, and your overall risk depends on other genetic and environmental factors.

Why Your Ancestry Changes the Interpretation

One of the most important things to understand about APOE4 results is that the risk numbers you see quoted most often come predominantly from studies of White populations, and the effect of carrying ε4 varies meaningfully across racial and ethnic groups. A landmark study found that the elevated risk of Alzheimer’s associated with one or more ε4 alleles was significant for White participants but was not statistically significant for African American or Hispanic participants by age 90.⁶ That does not mean ε4 is harmless in those groups. Among people who carry ε4, the cumulative risk of Alzheimer’s to age 90 was actually similar across all three ethnic groups. The difference was that African Americans and Hispanics without any ε4 had substantially higher baseline risk of Alzheimer’s than White people without ε4, which narrows the apparent gap that ε4 creates.⁶

The practical upshot: if you are not White, APOE4 results derived from predominantly White cohorts may overstate the incremental risk that ε4 adds for you personally, while potentially understating your overall Alzheimer’s risk from other factors. A genetic counselor familiar with these nuances can help put your results in the right context.

APOE4 and the New Alzheimer’s Drugs

The most immediate practical reason APOE testing has surged in relevance is the arrival of anti-amyloid antibody treatments like lecanemab. These drugs can cause a side effect called amyloid-related imaging abnormalities, or ARIA, which involves brain swelling or small bleeds visible on MRI. APOE4 carriers, especially homozygotes, face substantially higher ARIA rates, and this has made APOE genotyping a recommended part of treatment planning.

In the pivotal CLARITY AD trial of lecanemab, ARIA rates in ε4 noncarriers were about 5%, in heterozygous ε4 carriers about 11%, and in homozygous ε4/ε4 carriers roughly 33%. Symptomatic ARIA (the kind you actually feel) ran about 1.4%, 1.7%, and 9.2% across those same groups.⁷ A more recent study explored whether adjusting the dose based on APOE genotype could reduce this gap, and did find lower ARIA-E rates in homozygous carriers with a modified dosing schedule, though the risk remained elevated compared to noncarriers.⁸

The appropriate use recommendations for lecanemab explicitly recommend APOE genotyping for all patients who agree to it, so that risk conversations with patients and their families can be properly informed.⁷ If you or a family member is being considered for one of these therapies, knowing APOE status is no longer optional, it is part of the safety evaluation. Researchers have also found that combining APOE genotype with a blood biomarker called p-tau217 improves the ability to identify people with early Alzheimer’s pathology and to stratify patients for clinical trials.⁹

Cholesterol and Heart Health

APOE4’s effects extend well beyond the brain. The protein plays a major role in how your body handles cholesterol, and ε4 carriers tend to run higher levels of total cholesterol and LDL. In one neuroimaging cohort, ε4 carriers had significantly higher total cholesterol than both ε3 and ε2 carriers.¹⁰ The mechanism involves how APOE4 preferentially binds to certain fat-carrying particles in the blood, which leads to a downregulation of LDL receptors and, consequently, higher circulating LDL.¹¹

Interestingly, APOE2 also affects cardiovascular risk, but through a different path: it binds poorly to LDL receptors, which can raise levels of certain atherogenic lipoproteins.¹¹ So while ε2 is protective against Alzheimer’s, it is not entirely benign for cardiovascular health. If your result shows ε4, it is worth discussing lipid management with your doctor more proactively than you otherwise might. The cholesterol connection also creates a secondary pathway to brain health, since midlife cardiovascular risk factors are themselves associated with later cognitive decline.

The Emotional Side of Getting Results

Learning your APOE genotype can hit harder than people expect. A large pre-screening study of cognitively healthy adults found that disease-specific distress increased in the days after disclosure for ε4 homozygotes, as did anxiety levels. Heterozygotes and noncarriers, by contrast, actually saw a slight decrease in anxiety after learning their status. The reassuring finding was that for all groups, the increases in distress were small and did not reach levels of clinical concern.¹² No significant changes in depressive symptoms were observed for any genotype group.¹²

The longer-term picture is more encouraging. In a qualitative study of people who had learned they carried an elevated genetic risk for Alzheimer’s, a substantial fraction reported initial adverse reactions, but nearly all of them said in retrospect that they had benefited from the knowledge. The benefit came primarily from lifestyle changes they made afterward: improved diet, more exercise, better management of cardiovascular risk factors. As one participant put it, they were “much sharper than I was” before testing.¹³ Separate research has confirmed that ε4 carriers are more likely to make behavioral changes after disclosure than noncarriers.¹⁴

Insurance and Legal Protections

Before you test, it is worth understanding the legal landscape. In the United States, the Genetic Information Nondiscrimination Act (GINA) makes it illegal for health insurers and employers to discriminate based on genetic test results. However, GINA does not cover long-term care insurance, disability insurance, or life insurance.¹⁵ This gap matters because long-term care is exactly the type of coverage that Alzheimer’s risk makes more relevant. If you are considering purchasing long-term care or life insurance, some genetic counselors advise securing those policies before getting tested, since a positive ε4 result in your medical record could theoretically affect your ability to obtain coverage in those unprotected categories. State laws vary, and some states have additional genetic privacy protections. This is an area where talking to both a genetic counselor and an insurance advisor beforehand can save real trouble.

Diet, Exercise, and What You Can Actually Do

If your APOE genotype comes back with one or two ε4 alleles, the natural next question is what you can do about it. The gene is not something you can change, but its downstream effects appear to be modifiable to some degree. Two well-powered observational studies found that diets high in saturated fat increased the risk of cognitive decline, and that this risk was more pronounced in ε4 carriers than in noncarriers.¹⁶ The relationship between APOE4 and dietary fat makes biological sense given the protein’s role in lipid transport: if your version of the protein already handles fats inefficiently, flooding the system with saturated fat may compound the problem.

Research into the Mediterranean diet and APOE4 has found that the gene interacts with the plasma metabolome in ways that are specific to homozygous carriers. A study in Nature Medicine identified 49 significant interactions between blood metabolites and APOE4 genotype in relation to dementia risk, and all of these interactions were specific to ε4/ε4 homozygotes.¹⁷ This suggests that homozygous carriers have a distinct metabolic profile that may respond differently to dietary interventions than the general population, though the research is still early in translating these metabolic differences into specific dietary recommendations.

Exercise, blood pressure control, sleep quality, and managing diabetes risk are all standard recommendations for brain health that appear to matter even more for ε4 carriers. None of these interventions guarantee you will not develop Alzheimer’s, but the evidence consistently suggests they shift the odds.

Early Brain Changes in Carriers

One finding that often surprises people is how early APOE4-related brain differences can be detected. A review of neuroimaging research in young adults found that ε4 carriers already show differences in brain connectivity and activity patterns compared to noncarriers, and that these functional changes appear to precede any structural changes.¹⁸ A systematic review of cognitively healthy midlife adults reached a similar conclusion: ε4 carriers demonstrate measurable neurobiological differences consistent with a preclinical vulnerability, even when they have no cognitive symptoms whatsoever.¹⁹

These findings do not mean that young or middle-aged ε4 carriers are on an inevitable path to disease. What they suggest is that the biological process associated with ε4 begins decades before any symptoms appear, which opens a longer window for potential intervention. It also explains why researchers are increasingly interested in testing preventive therapies in ε4 carriers during midlife rather than waiting for cognitive decline to emerge.

APOE4 and Head Injury Recovery

An area of growing interest is the connection between APOE4 and outcomes after traumatic brain injury. Animal research using mice engineered to carry human APOE variants has shown that APOE4 mice had more inflammation, more neurodegeneration, and less of a key neuroprotective protein (BDNF) following repeated mild head injuries compared to APOE3 mice.²⁰ In humans, a study of brain bank donors who had experienced repetitive head impacts found that ε4 carriers older than 65 had significantly higher levels of the tau protein tangles characteristic of chronic traumatic encephalopathy (CTE), with an association size comparable to having played more than seven additional years of football.²¹

If you are an ε4 carrier involved in contact sports or occupations with head injury risk, this information is worth knowing and discussing with a physician, even if the clinical guidance for what to do differently is still evolving.

APOE4 and Lifespan

Beyond disease-specific risks, APOE4 appears to have a broader relationship with how long people live. A study comparing centenarians and younger healthy controls across three countries found that the ε4 allele was consistently less common among people who reached age 100. The odds ratios for carrying ε4 among centenarians were 0.55 in Spain, 0.41 in Italy, and 0.35 in Japan, all pointing in the same direction: ε4 carriers are underrepresented among the extremely long-lived.²² This likely reflects the cumulative burden of ε4’s effects on cardiovascular health, brain health, and other systems over a full lifetime, rather than any single cause of death. It is a statistical pattern across populations, not a ceiling on any individual carrier’s lifespan, but it reinforces the case for proactive health management if you carry the variant.

1
The Journal of Prevention of Alzheimer’s Disease. Editorial Implications of Emerging Uses of Genetic Testing for Alzheimer’s Disease
2
PubMed Central. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
3
PubMed Central. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
4
Trends in Endocrinology & Metabolism. Apolipoprotein E in lipid metabolism and neurodegenerative disease
5
JAMA Neurology. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
6
JAMA. The APOE-∊4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics
7
The Journal of Prevention of Alzheimer’s Disease. Lecanemab: Appropriate Use Recommendations
8
PubMed Central. APOE‐guided lecanemab dosing dissociates ARIA‐E from ARIA‐H: The K‐ROAD study
9
PubMed Central. Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer’s disease staging
10
PubMed Central. Total Cholesterol and APOE-Related Risk for Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative
11
PubMed Central. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders
12
PubMed Central. Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer’s Prevention Initiative Generation Study 1
13
Genetics in Medicine. “Well, good luck with that”: reactions to learning of increased genetic risk for Alzheimer disease
14
PubMed Central. Tele-Genetic Versus Onsite Counseling for APOE Disclosure: A 6-Month Study of Empowerment, Psychological Distress, and Behavioral Outcomes in Cognitively Diverse Individuals
15
PubMed Central. Genetic Testing For Alzheimer’s And Long-Term Care Insurance
16
PubMed Central. A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE ε4 Carriers
17
Nature Medicine. Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function
18
Ageing Research Reviews. The effects of APOEe4 allele on cerebral structure, function, and related interactions with cognition in young adults
19
NeuroImage: Clinical. Impact of apolipoprotein Ε4 (APOE ε4) on neuroimaging outcomes in cognitively healthy midlife adults: A systematic review
20
Scientific Reports. APOE4 genetic polymorphism results in impaired recovery in a repeated mild traumatic brain injury model and treatment with Bryostatin-1 improves outcomes
21
JAMA Neurology. Association of APOE Genotypes and Chronic Traumatic Encephalopathy
22
Experimental Gerontology. ApoE gene and exceptional longevity: Insights from three independent cohorts